SAVELLA (milnacipran hydrochloride) by AbbVie is unknown. Approved for fibromyalgia (). First approved in 2009.
Drug data last refreshed 5h ago · AI intelligence enriched Yesterday
SAVELLA (milnacipran hydrochloride) is an oral small-molecule SNRI approved for fibromyalgia, a chronic pain condition affecting millions of patients globally. The drug works by inhibiting neuronal reuptake of norepinephrine and serotonin, with approximately 3-fold higher potency for norepinephrine, thereby modulating pain signaling in the CNS. Milnacipran does not bind significantly to dopamine, muscarinic, histaminergic, adrenergic, or opioid receptors, resulting in a relatively clean pharmacologic profile.
Product is at peak commercial maturity with $61M annual spending in 2023, indicating a stable, mid-sized commercial franchise requiring experienced brand management and field support teams.
unknown. Preclinical studies have shown that milnacipran is a potent inhibitor of neuronal norepinephrine and serotonin reuptake; milnacipran inhibits norepinephrine uptake with approximately 3-fold higher potency in vitro than serotonin without directly affecting the uptake of dopamine or other…
The Savella Pregnancy Registry
Worked on SAVELLA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moAbbVie is hiring 1 role related to this product
LOE in ~3 years — strategic planning for patent cliff underway
SAVELLA offers limited but focused career opportunities, with only 1 linked position primarily in Spanish-language field sales, reflecting a mature product with smaller commercial footprint. Roles center on field execution, customer engagement, and market access rather than expansive brand building or clinical development.
1 open roles linked to this drug